<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03368352</url>
  </required_header>
  <id_info>
    <org_study_id>170200</org_study_id>
    <nct_id>NCT03368352</nct_id>
  </id_info>
  <brief_title>Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.</brief_title>
  <official_title>Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low oxygen at altitude causes pauses in breathing during sleep, called central sleep apnea.&#xD;
      Central sleep apnea causes repeated awakenings and poor sleep. Low oxygen itself and the&#xD;
      induced oxidative stress can damage mental function which is likely worsened by poor sleep.&#xD;
      Reduced mental function due to low oxygen can pose a serious danger to mountain climbers.&#xD;
      However there is also mounting evidence that even in populations of people that live at high&#xD;
      altitudes and are considered adapted, low oxygen contributes to reductions in learning and&#xD;
      memory. Therefore there is a serious need for treatments which may improve sleep, control of&#xD;
      breathing and mental function during low oxygen. Melatonin is a hormone produced in the brain&#xD;
      during the night which regulates sleep patterns with strong antioxidant and anti-inflammatory&#xD;
      properties. A study previously reported that melatonin taken 90 mins before bed at 4,300 m&#xD;
      (14,200 ft) induced sleep earlier, reduced awakenings and improved mental performance the&#xD;
      following day. However how melatonin caused these effects was not determined. Therefore this&#xD;
      study aims to determine how melatonin effects control of breathing, sleep and mental&#xD;
      performance during exposure to low oxygen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2017</start_date>
  <completion_date type="Actual">December 20, 2018</completion_date>
  <primary_completion_date type="Actual">December 20, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo controlled</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>30 minutes after arousal from sleep</time_frame>
    <description>Stroop-color word test median number of errors. Higher numbers indicate worse performance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>5 minutes after arousal from sleep</time_frame>
    <description>Reactive hypermedia index via EndoPat</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid peroxidation in serum</measure>
    <time_frame>immediately after arousal from sleep</time_frame>
    <description>Concentration of Malondialdehyde in serum samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypercapnic hypoxic ventilatory sensitivity</measure>
    <time_frame>1 hour after arousal from sleep</time_frame>
    <description>This is the one outcome. It is the gain of the ventilatory response to changes in CO2, during sustained hypoxia. Delta minute ventilation / delta mmHg CO2 during sustained hypoxia</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Altitude Hypoxia</condition>
  <condition>Ventilation</condition>
  <condition>Sleep</condition>
  <condition>Oxidative Stress</condition>
  <condition>Neurocognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>Normoxia</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Sleep in normal room air with no drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypoxia with Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sleep in hypoxic tent after taking Placebo 1 hour before bed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypoxia with Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sleep in hypoxic tent after taking 5 mg Melatonin before bed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Dietary supplement melatonin</description>
    <arm_group_label>Hypoxia with Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypoxia</intervention_name>
    <description>Sleep in a hypoxic tent simulating high altitude</description>
    <arm_group_label>Hypoxia with Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sleep disorders&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Smokers (quit â‰¥ 1 year ago acceptable)&#xD;
&#xD;
          -  Any known cardiac (apart from treated hypertension with acceptable drugs, see below),&#xD;
             pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular,&#xD;
             hepatic disease, or patients with diabetes.&#xD;
&#xD;
          -  Prior or current use of melatonin.&#xD;
&#xD;
          -  Use of any medications that may affect sleep or breathing, blood-thinning medications&#xD;
             (anticoagulants), antioxidants, anti-inflammatories, medications that suppress the&#xD;
             immune system (immunosuppressants), diabetes medications and birth control pills.&#xD;
&#xD;
          -  A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar&#xD;
             disorder, major depression, panic or anxiety disorders.&#xD;
&#xD;
          -  Substantial alcohol (&gt;3oz/day) or use of illicit drugs.&#xD;
&#xD;
          -  Previous occurrence of high altitude pulmonary or cerebral edema.&#xD;
&#xD;
          -  Recent exposure to altitude (&gt;8000ft) in the last month or having slept at an altitude&#xD;
             &gt;6000ft in the last month.&#xD;
&#xD;
          -  Inability to provide written informed consent or able to complete the experiment.&#xD;
&#xD;
          -  Non-English speakers (necessary to complete neurocognitive testing).&#xD;
&#xD;
          -  More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSD Sleep Lab</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2017</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Naomi Deacon</investigator_full_name>
    <investigator_title>Research Scholar</investigator_title>
  </responsible_party>
  <keyword>Melatonin</keyword>
  <keyword>Altitude</keyword>
  <keyword>Sleep</keyword>
  <keyword>Ventilation</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

